Complement Therapeutics is a Munich-based biotech that dosed the first patient in Opti-GAIN, its Phase I/II study of CTx001, in early 2026. The AAV-based gene therapy targets geographic atrophy secondary to AMD — which affects 5 million people globally — with a single subretinal injection aiming for durable effect where current anti-VEGF treatments need indefinite repeat visits. The trial is international and carries FDA Fast Track designation.